WuXi XDC Cayman Inc. (HKG:2268)

Market Cap	82.15B +137.7%
Revenue (ttm)	5.58B +82.0%
Net Income	1.45B +123.2%
EPS	1.12 +107.4%
Shares Out	1.26B
PE Ratio	58.39
Forward PE	38.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,055,426
Average Volume	4,348,580
Open	64.65
Previous Close	64.65
Day's Range	63.75 - 65.65
52-Week Range	24.70 - 85.50
Beta	-2.13
RSI	50.23
Earnings Date	Mar 23, 2026

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China....

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2013
• Employees: 2,270
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2268

Financial Performance

In 2024, WuXi XDC Cayman's revenue was 4.05 billion, an increase of 90.80% compared to the previous year's 2.12 billion. Earnings were 1.07 billion, an increase of 277.24%.

Financial numbers in CNY